Umbilical cord serum therapy in acute ocular chemical burns
ISRCTN | ISRCTN08131903 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN08131903 |
Secondary identifying numbers | N/A |
- Submission date
- 04/06/2010
- Registration date
- 05/07/2010
- Last edited
- 06/04/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Injury, Occupational Diseases, Poisoning
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Rasik Vajpayee
Scientific
Scientific
Centre for Eye Research Australia
University of Melbourne
Royal Victorian Eye and Ear Hospital
32, Gisborne Street, East Melbourne
Victoria
Melbourne
3002
Australia
rasikv@unimelb.edu.au |
Study information
Study design | Double blind prospective randomised controlled clinical trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please contact Dr Manik Goel [manikgoel_aiims99@yahoo.com] to request a patient information sheet |
Scientific title | Evaluation of umbilical cord serum therapy in acute ocular chemical burns: a prospective, double-blind, randomised controlled trial |
Study objectives | The primary objectives of therapy in a case of acute ocular chemical burns are promotion of epithelialisation, reduction of inflammation, support of the reparative processes and prevention of complications. The standard medical treatment used in acute ocular chemical burns comprises of topical steroids, topical antibiotics, mydriatic cycloplegic, anti-glaucoma therapy, citrate and ascorbate. Autologous serum drops have been shown to be effective in the treatment of various ocular surface disorders including neurotrophic keratitis, severe dry eye, persistent epithelial defects and recurrent corneal erosions. Umbilical cord serum has been shown to be safe and effective in the treatment of neurotrophic keratitis, dry eye syndrome and persistent epithelial defects. Both autologous serum and umbilical cord serum owe their efficacy to the presence of various growth factors like epidermal growth factor (EGF), acidic and basic fibroblast growth factor (FGF), platlet-derived growth factor, hepatocyte growth factor, vitamin A, transforming growth factor ß (TGF-ß), substance P, IGF-1 (insulin like growth factor-1), nerve growth factor (NGF), fibronectin and serum antiproteases such as a2 macroglobulin. The concentrations of EGF, TGF-ß and NGF are several times higher in umbilical cord serum than peripheral blood serum. In the present study we tested the hypothesis, that umbilical cord serum with its higher concentration of these growth factors may promote an early healing of the ocular surface in cases of chemical burns. |
Ethics approval(s) | All India Institute of Medical Sciences, New Delhi, India approved on the 15th of September 2005 |
Health condition(s) or problem(s) studied | Acute chemical ocular burns |
Intervention | 1. Patients were started on standard medical therapy consisting of: 1.1. Topical ofloxacin hydrochloride 0.3% 6-hourly 1.2. Topical prednisolone acetate 1% 2-hourly 1.3. Topical homatropine 2% three times daily (tds) 1.4. Topical ascorbate 10% 2-hourly 1.5. Topical citrate 10% 2-hourly 1.6. Oral vitamin C 500 mg four times daily (qid) 1.7. Preservative free topical lubricants 2-hourly 1.8. Topical anti-glaucoma medications (if required) in the form of timolol maleate eye drops 0.5% bid and/or oral acetazolamide 250 mg tds 2. Patients were then divided into three groups: 2.1. Group I received 20% umbilical cord serum drops 10 times a day 2.2. Group II received 20% autologous serum drops 10 times a day 2.3. Group III received artificial tear drops (0.5% hydroxypropylmethylcellulose and 0.3% glycerin) 10 times a day |
Intervention type | Other |
Primary outcome measure | Patients were followed up on day 1, day 3, day 7, day 14, day 21 and at the end of 1 month, 2 months and 3 months. Total duration of follow up in all three groups was 3 months. Parameters assessed were at each follow-up included: 1. Pain score 2. Best corrected visual acuity 3. Limbal ischaemia 4. Epithelial defect 5. Corneal clarity and vascularisation 6. Tear film status (Schirmer, TBUT) 7. Intraocular pressure (IOP) 8. Symblepharon formation |
Secondary outcome measures | Complications arising from injury and/or treatment |
Overall study start date | 01/09/2005 |
Completion date | 01/07/2007 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 33 eyes of 32 patients |
Key inclusion criteria | 1. Patients with acute ocular chemical burns (grade III, IV and V according to Dua classification) presenting within three weeks of injury 2. Either sex, aged 16 - 50 years |
Key exclusion criteria | 1. Patients with grade I, II and VI injury 2. Impending perforation |
Date of first enrolment | 01/09/2005 |
Date of final enrolment | 01/07/2007 |
Locations
Countries of recruitment
- Australia
- India
Study participating centre
Centre for Eye Research Australia
Melbourne
3002
Australia
3002
Australia
Sponsor information
Dr Rajendra Prasad Centre for Ophthalmic Sciences (India)
Hospital/treatment centre
Hospital/treatment centre
Ansari Nagar
New Delhi
3002
India
rasikv@unimelb.edu.au | |
https://ror.org/02dwcqs71 |
Funders
Funder type
Hospital/treatment centre
Dr RP Centre for Ophthalmic Sciences (India) - Hospital infrastructure and resources
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 25/02/2011 | Yes | No |